AAV Antibodies
Adeno-associated virus (AAV) antibodies reflect prior exposure to AAV vectors and can impact eligibility and efficacy of gene therapies that use AAV-based delivery. Pre-existing antibodies may neutralize the vector and are commonly assessed before treatment.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where AAV Antibodies is defined directly in the indication labeling.
Approvals defined at the solid tumor level where AAV Antibodies is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report AAV Antibodies as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports AAV Antibodies as part of its biomarker panel.
Reports AAV Antibodies as part of its biomarker panel.
Reports AAV Antibodies as part of its biomarker panel.